HRP20180226T1 - Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc - Google Patents
Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc Download PDFInfo
- Publication number
- HRP20180226T1 HRP20180226T1 HRP20180226TT HRP20180226T HRP20180226T1 HR P20180226 T1 HRP20180226 T1 HR P20180226T1 HR P20180226T T HRP20180226T T HR P20180226TT HR P20180226 T HRP20180226 T HR P20180226T HR P20180226 T1 HRP20180226 T1 HR P20180226T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- gram
- bacterial cell
- negative bacterial
- antibody
- Prior art date
Links
- 230000001580 bacterial effect Effects 0.000 title claims 17
- 210000004027 cell Anatomy 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 101150081864 Spr gene Proteins 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 229920001427 mPEG Polymers 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- -1 poly(ethylene glycol) Polymers 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241001646716 Escherichia coli K-12 Species 0.000 claims 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 101150052672 IGS1 gene Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 210000001322 periplasm Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Claims (15)
1. Rekombinantna gram-negativna bakterijska stanica koja sadrži:
a) ekspresijski vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC; i
b) jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih koji se specifično veže za CD154;
c) mutirani Tsp gen koji kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze divljeg tipa ne-mutiranog Tsp proteina kao što je prikazano u SEK ID BR: 26 i;
d) mutirani spr gen koji kodira spr protein čija je sekvenca divljeg tipa prikazana u SEK ID BR: 24 uključujući
mutaciju koja utječe na aminokiselinu C94; i
pri čemu je navedena gram-negativna bakterijska stanica izabrana od sojeva E. coli K12 i W3110, i pri čemu je bakterijska stanica izogen za navedene sojeve, osim za rekombinantni polinukleotid koji kodira DsbC, jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih koji se specifično veže za CD154 i mutirani Tsp gen i mutirani spr gen.
2. Gram-negativna bakterijska stanica prema patentnom zahtjevu 1, naznačena time da DsbC sadrži histidin–tag na N-terminusu ili C-terminusu.
3. Gram-negativna bakterijska stanica prema patentnom zahtjevu 1 ili 2, naznačena time da ekspresijski vektor sadrži polinukleotid koji ima sekvencu danu u SEK ID BR: 45 ili SEK ID BR: 51.
4. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time da antitijelo ili antigen vezujući fragment od njih sadrži varijabilnu domenu teškog lanca koja sadrži tri CDR-a koji imaju sekvencu danu u SEK ID BR: 1 za CDRH1, SEK ID BR: 2, za CDRH2 i SEK ID BR: 3 za CDRH3 i varijabilnu domenu lakog lanca koji sadrži tri CDR-a koji imaju sekvencu danu u SEK ID BR: 4 za CDRL1, SEK ID BR: 5 za CDRL2 i SEK ID BR: 6 za CDRL3.
5. Gram-negativna bakterijska stanica prema patentnom zahtjevu 4, naznačena time da jedan ili više polinukleotida kodiraju antitijelo koje sadrži sekvencu varijabilne regije lakog lanca danu u SEK ID BR: 8 i varijabilnu regiju teškog lanca danu u SEK ID BR: 10.
6. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time da je antitijelo Fab ili Fabov fragment.
7. Gram-negativna bakterijska stanica prema patentnom zahtjevu 6, naznačena time da Fab ili Fabov fragment sadrži laki lanac koji ima sekvencu danu u SEK ID BR: 12 i teški lanac, koji ima sekvencu danu u SEK ID BR: 14 ili 16.
8. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time da gram-negativna bakterijska stanica sadrži prvi ekspresijski vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC i drugi ekspresijski vektor koji sadrži jedan ili više polinukleotida koji kodiraju antitijelo ili antigen koji veže fragment od njih, posebno koji veže CD154.
9. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time da ekspresijski vektor, koji sadrži rekombinantni polinukleotid koji kodira DsbC, dodatno sadrži jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih, posebno koji veže CD154.
10. Gram-negativna bakterijska stanica prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da mutacija u spr genu koji kodira spr protein, rezultira u promjeni aminokiselinskog cisteina u alanin na poziciji 94 (C94A).
11. Gram-negativna bakterijska stanica prema bilo kojem od patentnih zahtjeva 1 do 10, koji sadrži ekspresijski vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC i dicistronsku poruku za proizvodnju antitijela ili antigen vezujućeg fragmenta od njih, posebno koji veže CD154, u kojem uzvodni cistron sadrži DNA koja kodira laki lanac antitijela i nizvodni cistron sadrži DNA koja kodira odgovarajući teški lanac, naznačena time da dicistronska poruka sadrži sekvencu izabranu od IGS1 (SEK ID BR: 33), IGS2 (SEK ID BR:34), IGS3 (SEK ID BR: 35) i IGS4 (SEK ID BR: 36).
12. Postupak za proizvodnju antitijela ili antigen vezujućeg fragmenta od njih posebno koji veže CD154, naznačen time da sadži:
a) kultiviranje rekombinantne gram-negativne bakterijske stanice kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 11 u mediju kulture pod uvjetima efikasnim da eksprimiraju antitijelo ili antigen vezujući fragment od njih, posebno koji veže CD154 i rekombinantni polinukleotid koji kodira DsbC; i
b) obnavljanje antitijela ili antigen vezujućeg fragmenta od njih, posebno koji veže CD154 iz periplazme rekombinantne gram-negativne bakterijske stanice i/ili medija kulture.
13. Postupak prema patentnom zahtjevu 12, naznačen time da postupak dalje sadrži korak spajanja efektorske molekule na aminokiselinu na ili prema C-terminalnom kraju teškog lanca i/ili lakog lanca antitijela.
14. Postupak prema patentnom zahtjevu 13, naznačen time da efektorska molekula sadrži poli(etilenglikol) ili metoksipoli(etilenglikol).
15. Postupak prema patentnom zahtjevu 14, naznačen time da postupak sadrži vezanje na jedan od cisteinskih ostataka na C-terminalnom kraju teškog lanca lizil-maleimidne skupine, pri čemu svaka amino skupina lizil ostatka ima kovalentno povezan sa njim metoksipoli(etilenglikol) ostatak koji ima molekulsku težinu od oko 20,000 Da.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173880 | 2011-07-13 | ||
| EP12737492.4A EP2731973B1 (en) | 2011-07-13 | 2012-07-13 | Bacterial host strain expressing recombinant dsbc |
| PCT/EP2012/002945 WO2013007388A1 (en) | 2011-07-13 | 2012-07-13 | Bacterial host strain expressing recombinant dsbc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180226T1 true HRP20180226T1 (hr) | 2018-03-09 |
Family
ID=46545736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180226TT HRP20180226T1 (hr) | 2011-07-13 | 2018-02-06 | Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9725516B2 (hr) |
| EP (2) | EP2731973B1 (hr) |
| JP (3) | JP6431370B2 (hr) |
| KR (1) | KR102023786B1 (hr) |
| CN (1) | CN103649124B (hr) |
| AU (1) | AU2012283388B2 (hr) |
| BR (1) | BR112013032871B1 (hr) |
| CA (1) | CA2841824C (hr) |
| CY (1) | CY1119985T1 (hr) |
| DK (1) | DK2731973T3 (hr) |
| EA (1) | EA031449B1 (hr) |
| ES (1) | ES2659155T3 (hr) |
| HK (1) | HK1194393A1 (hr) |
| HR (1) | HRP20180226T1 (hr) |
| HU (1) | HUE035674T2 (hr) |
| IL (1) | IL229947B (hr) |
| IN (1) | IN2014DN00202A (hr) |
| LT (1) | LT2731973T (hr) |
| ME (1) | ME02957B (hr) |
| MX (1) | MX348738B (hr) |
| NO (1) | NO2731973T3 (hr) |
| PL (1) | PL2731973T3 (hr) |
| PT (1) | PT2731973T (hr) |
| RS (1) | RS56926B1 (hr) |
| SG (1) | SG10201807560XA (hr) |
| SI (1) | SI2731973T1 (hr) |
| WO (1) | WO2013007388A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2125894T1 (sl) * | 2007-03-22 | 2019-05-31 | Biogen Ma Inc. | Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe |
| HUE040306T2 (hu) | 2009-09-24 | 2019-03-28 | Ucb Biopharma Sprl | Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| SI2731973T1 (en) * | 2011-07-13 | 2018-04-30 | Ucb Biopharma Aprl | A bacterial host strain expressing a recombinant DSBC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| HRP20231408T1 (hr) | 2014-12-22 | 2024-02-16 | UCB Biopharma SRL | Proizvodnja proteina |
| KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
| CN108495653A (zh) | 2016-01-27 | 2018-09-04 | 免疫医疗有限责任公司 | 用于制备具有定义的糖基化模式抗体的方法 |
| TW202031899A (zh) * | 2018-11-05 | 2020-09-01 | 美商建南德克公司 | 在原核宿主細胞中產生二鏈蛋白質之方法 |
| CN109371049A (zh) * | 2018-11-14 | 2019-02-22 | 天津大学 | 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用 |
| JP2022525775A (ja) | 2019-03-18 | 2022-05-19 | バイオ－ラッド エービーディー セロテック ゲーエムベーハー | ＳｐｙＴａｇ含有ペリプラズム融合タンパク質のプロテアーゼＴＳＰ及びＯＭＰＴ分解からの保護 |
| CN114829578A (zh) * | 2019-08-05 | 2022-07-29 | 瓦克化学股份公司 | 用于在发酵方法中释放重组蛋白的细菌菌株 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| JPH08500963A (ja) | 1992-04-28 | 1996-02-06 | ザ・リージェンツ・オブ・ザ・ユニヴァーシティー・オブ・ミシガン | ヒューマンｃｒａｂｐ−▲ｉ▼及びｃｒａｂｐ−▲ｉｉ▼ |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5304472A (en) | 1992-11-20 | 1994-04-19 | Genentech, Inc. | Method of controlling polypeptide production in bacterial cells |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| JP2000083670A (ja) | 1998-09-09 | 2000-03-28 | Hsp Kenkyusho:Kk | ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド |
| ATE343790T1 (de) | 1999-06-29 | 2006-11-15 | Siga Technologies Inc | Test für degp-protease inhibitoren |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU2001287040A1 (en) | 2000-09-01 | 2002-03-13 | Biogen, Inc. | Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| US7041479B2 (en) | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| AU2002245142B2 (en) * | 2000-12-14 | 2007-07-05 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
| AU3957602A (en) | 2000-12-14 | 2002-06-24 | Genentech Inc | Bacterial host strains |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| MXPA04001566A (es) | 2001-08-27 | 2004-05-17 | Genentech Inc | Un sistema para expresion y ensamblado de anticuerpos. |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| EA007905B1 (ru) | 2001-11-16 | 2007-02-27 | Байоджен Айдек Инк. | Полицистронная экспрессия антител |
| GB0129105D0 (en) * | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| SI1517921T1 (sl) | 2002-06-28 | 2006-10-31 | Domantis Ltd | Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| JP4667383B2 (ja) | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用 |
| AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005011376A2 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc | Altered antibodies having improved antigen-binding affinity |
| RS20070027A (en) | 2004-07-26 | 2008-11-28 | Biogen Idec Ma Inc., | Anti-cd154 antibodies |
| MX2007002856A (es) * | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0425534D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| GB0520169D0 (en) | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| SI2125894T1 (sl) | 2007-03-22 | 2019-05-31 | Biogen Ma Inc. | Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe |
| EP2535351A3 (en) | 2007-09-26 | 2013-04-03 | UCB Pharma S.A. | Dual specificity antibody fusions |
| US7662587B1 (en) | 2009-03-05 | 2010-02-16 | E. I. Du Pont De Nemours And Company | Gene knockout mutations that increase peptide production |
| HUE040306T2 (hu) | 2009-09-24 | 2019-03-28 | Ucb Biopharma Sprl | Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| ES2636971T3 (es) | 2009-11-05 | 2017-10-10 | F. Hoffmann-La Roche Ag | Procedimientos y composición para la secreción de polipéptidos heterógenos |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000588D0 (en) * | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| SI2731973T1 (en) * | 2011-07-13 | 2018-04-30 | Ucb Biopharma Aprl | A bacterial host strain expressing a recombinant DSBC |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
-
2012
- 2012-07-13 SI SI201231206T patent/SI2731973T1/en unknown
- 2012-07-13 HU HUE12737492A patent/HUE035674T2/en unknown
- 2012-07-13 CA CA2841824A patent/CA2841824C/en active Active
- 2012-07-13 ES ES12737492.4T patent/ES2659155T3/es active Active
- 2012-07-13 AU AU2012283388A patent/AU2012283388B2/en active Active
- 2012-07-13 EA EA201490274A patent/EA031449B1/ru not_active IP Right Cessation
- 2012-07-13 EP EP12737492.4A patent/EP2731973B1/en active Active
- 2012-07-13 KR KR1020137034718A patent/KR102023786B1/ko active IP Right Grant
- 2012-07-13 PL PL12737492T patent/PL2731973T3/pl unknown
- 2012-07-13 JP JP2014519454A patent/JP6431370B2/ja active Active
- 2012-07-13 BR BR112013032871-1A patent/BR112013032871B1/pt active IP Right Grant
- 2012-07-13 RS RS20180171A patent/RS56926B1/sr unknown
- 2012-07-13 US US14/131,994 patent/US9725516B2/en active Active
- 2012-07-13 MX MX2014000302A patent/MX348738B/es active IP Right Grant
- 2012-07-13 NO NO12737492A patent/NO2731973T3/no unknown
- 2012-07-13 SG SG10201807560XA patent/SG10201807560XA/en unknown
- 2012-07-13 EP EP17196968.6A patent/EP3339325A1/en not_active Withdrawn
- 2012-07-13 CN CN201280034512.9A patent/CN103649124B/zh active Active
- 2012-07-13 IN IN202DEN2014 patent/IN2014DN00202A/en unknown
- 2012-07-13 DK DK12737492.4T patent/DK2731973T3/da active
- 2012-07-13 PT PT127374924T patent/PT2731973T/pt unknown
- 2012-07-13 ME MEP-2018-33A patent/ME02957B/me unknown
- 2012-07-13 WO PCT/EP2012/002945 patent/WO2013007388A1/en active Application Filing
- 2012-07-13 LT LTEP12737492.4T patent/LT2731973T/lt unknown
-
2013
- 2013-12-17 IL IL22994713A patent/IL229947B/en active IP Right Grant
-
2014
- 2014-07-30 HK HK14107814.3A patent/HK1194393A1/zh unknown
-
2017
- 2017-08-03 US US15/667,649 patent/US9957328B2/en active Active
- 2017-10-31 JP JP2017209932A patent/JP2018019719A/ja active Pending
-
2018
- 2018-02-06 HR HRP20180226TT patent/HRP20180226T1/hr unknown
- 2018-02-15 CY CY20181100192T patent/CY1119985T1/el unknown
-
2019
- 2019-11-01 JP JP2019200029A patent/JP7062626B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180226T1 (hr) | Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc | |
| JP2021020905A5 (hr) | ||
| JP2018085988A5 (hr) | ||
| JP2014521313A5 (hr) | ||
| HRP20190897T1 (hr) | Laki lanac humaniziranih miševa | |
| TWI713942B (zh) | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 | |
| ES2649098T3 (es) | Anticuerpos de unión a albumina y fragmentos de unión de los mismos | |
| JP2021106617A5 (hr) | ||
| Borras et al. | Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies | |
| RU2016119152A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| Chan et al. | Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays | |
| JP2018502572A5 (hr) | ||
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| JP2018521638A5 (hr) | ||
| JP2005535301A5 (hr) | ||
| HRP20170852T1 (hr) | Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc i ima reduciranu tsp aktivnost | |
| JP2010502183A5 (hr) | ||
| RU2013124808A (ru) | Новое антитело против dr5 | |
| JP2014515921A5 (hr) | ||
| DK2921503T3 (en) | Human antibody to human epidermal growth factor receptor and coding gene and its use | |
| JP2014158485A5 (hr) | ||
| JP2020524510A5 (hr) | ||
| EP2668206A1 (en) | Engineering of immunoglobulin domains | |
| JP2017509323A5 (hr) | ||
| JP2011505810A5 (hr) |